SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical Industries reply to clarification sought by the exchange

30 Apr 2015 Evaluate
The Exchange had sought clarification from Sun Pharmaceutical Industries with respect to news article appearing in Financial Chronicle on April 29, 2015 titled ‘Sun Pharma ready to spend $7b on M&A’. Sun Pharmaceutical Industries replied stating that the Company has no comments on this article ‘Sun Pharma ready to spend $7b on M&A’. Please further note that the Company has neither substantiated nor confirmed this information to the media.

The above information is a part of company’s filings submitted to BSE.


Sun Pharma Inds. Share Price

1673.45 -1.75 (-0.10%)
20-Apr-2026 09:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.45
Dr. Reddys Lab 1235.10
Cipla 1233.00
Zydus Lifesciences 939.95
Lupin 2330.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×